CoChat

Liver Fibrosis: From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells

Open access
Akkız, Hikmet, Gieseler, Robert K., Canbay, Ali · 2024 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 224 of the 224 references it cites were found in a registry or an index.

Abstract

The burden of chronic liver disease is globally increasing at an alarming rate. Chronic liver injury leads to liver inflammation and fibrosis (LF) as critical determinants of long-term outcomes such as cirrhosis, liver cancer, and mortality. LF is a wound-healing process characterized by excessive deposition of extracellular matrix (ECM) proteins due to the activation of hepatic stellate cells (HSCs). In the healthy liver, quiescent HSCs metabolize and store retinoids. Upon fibrogenic activation, quiescent HSCs transdifferentiate into myofibroblasts; lose their vitamin A; upregulate α-smooth muscle actin; and produce proinflammatory soluble mediators, collagens, and inhibitors of ECM degradation. Activated HSCs are the main effector cells during hepatic fibrogenesis. In addition, the accumulation and activation of profibrogenic macrophages in response to hepatocyte death play a critical role in the initiation of HSC activation and survival. The main source of myofibroblasts is resident HSCs. Activated HSCs migrate to the site of active fibrogenesis to initiate the formation of a fibrous scar. Single-cell technologies revealed that quiescent HSCs are highly homogenous, while activated HSCs/myofibroblasts are much more heterogeneous. The complex process of inflammation results from the response of various hepatic cells to hepatocellular death and inflammatory signals related to intrahepatic injury pathways or extrahepatic mediators. Inflammatory processes modulate fibrogenesis by activating HSCs and, in turn, drive immune mechanisms via cytokines and chemokines. Increasing evidence also suggests that cellular stress responses contribute to fibrogenesis. Recent data demonstrated that LF can revert even at advanced stages of cirrhosis if the underlying cause is eliminated, which inhibits the inflammatory and profibrogenic cells. However, despite numerous clinical studies on plausible drug candidates, an approved antifibrotic therapy still remains elusive. This state-of-the-art review presents cellular and molecular mechanisms involved in hepatic fibrogenesis and its resolution, as well as comprehensively discusses the drivers linking liver injury to chronic liver inflammation and LF.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms25147873

Cites

224 of 224 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Overview of the cellular and molecular mechanisms of liver fibrogenesis. During chronic liver injury, hepatocytes activate signaling via Janus kinase (JNK), Notch, osteopontin, and hedgehog and produce exosomes harboring microRNAs (miRNAs) to initiate HSC activation. Inflammation triggers KCs and recruits monocyte-derived macrophages through C-C motif chemokine receptor (CCR)9 and C-C motif chemokine ligand (CCL)2, CCl4, and CCL25. The crosstalk between C-X3-C motif chemokine ligand 1 (CX3CL1) and C-X3-C motif chemokine receptor 1 (CX3CR1) orchestrates macrophage survival, differentiation, and polarization. KCs trigger the HSC activation by TGF-β, PDGF, and IL-1-β. Activated HSCs produce ECM proteins and secrete inflammatory chemokines CCL2, CCL3, and CX3CL1, whereby accumulating proinflammatory monocytes. HSC-originated matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) contribute to ECM perpetuation, remodeling, and fibrosis. Activated HSCs lead to portal hypertension by enhancing the hepatic sinusoids’ contractility. Some molecules and pathways, including endothelin 1, TGF-β, Jak2, and the Wnt/β/catenin pathway, affect sinusoidal contractility.
Figure 1 Overview of the cellular and molecular mechanisms of liver fibrogenesis. During chronic liver injury, hepatocytes activate signaling via Janus kinase (JNK), Notch, osteopontin, and hedgehog and produce exosomes harboring microRNAs (miRNAs) to initiate HSC activation. Inflammation triggers KCs and recruits monocyte-derived macrophages through C-C motif chemokine receptor (CCR)9 and C-C motif chemokine ligand (CCL)2, CCl4, and CCL25. The crosstalk between C-X3-C motif chemokine ligand 1 (CX3CL1) and C-X3-C motif chemokine receptor 1 (CX3CR1) orchestrates macrophage survival, differentiation, and polarization. KCs trigger the HSC activation by TGF-β, PDGF, and IL-1-β. Activated HSCs produce ECM proteins and secrete inflammatory chemokines CCL2, CCL3, and CX3CL1, whereby accumulating proinflammatory monocytes. HSC-originated matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) contribute to ECM perpetuation, remodeling, and fibrosis. Activated HSCs lead to portal hypertension by enhancing the hepatic sinusoids’ contractility. Some molecules and pathways, including endothelin 1, TGF-β, Jak2, and the Wnt/β/catenin pathway, affect sinusoidal contractility.CC BY · PubMed Central
Figure 2 Molecular pathways and cellular interactions involved in HSC activation and deactivation. Activated HSCs are the main effector cells during hepatic fibrosis. In the healthy liver, they metabolize and store retinoids. Upon activation by fibrogenic stimuli, quiescent HSCs transdifferentiate into myofibroblasts, lose their vitamin A, upregulate α-smooth muscle actin (αSMA), and produce collagen I. Various factors, including immune cell-derived fibrogenic molecules, growth factors, and lipopolysaccharide, as well as profibrotic lipid mediators such as lysophosphatidylinositol and lysophosphatidic acid, induce HSC activation in the course of chronic liver disease. TGF-β is the most HSC potent activator, which is produced by infiltrating lymphocytes and monocytes, Kupffer cells (KCs), and damaged hepatocytes. IL-17, produced by neutrophils and Th17 cells, sensitizes HSCs to TGF-β by upregulating TGF-β receptor II (TGF-βRII). In addition, platelet-derived growth factor (PDGF), which is produced by endothelial cells and macrophages, further promotes HSC activation. During fibrosis resolution, HSCs either die or revert to an inactive state by upregulating transcription factors such as peroxisome proliferator-activated receptor-γ (PPARγ), GATA-binding factor 4 (GATA4), GATA6, and transcription factor 21 (TCF21). NK and CD8+ T cells can eliminate activated HSCs by inducing apoptosis (Further abbreviations: GM-CSF, granulocyte/macrophage colony-stimulating factor; HH, hedgehog ligands; IHH, Indian Hedgehog; LPA, lysophosphatidic acid; LPI, lysophosphatidylinositol; LPS, lipopolysaccharide; miRNA, microRNA; MSR1, macrophage scavenger receptor 1; NF-κB, nuclear factor κ-light chain-enhancer of activated B cells; OPN, osteopontin; oxLDL, oxidized low-density lipoprotein; ROS, reactive oxygen species; S1P, sphingosine-1-phosphate; SHH, sonic hedgehog; TLR4, Toll-like receptor 4). Modified from reference [5].
Figure 2 Molecular pathways and cellular interactions involved in HSC activation and deactivation. Activated HSCs are the main effector cells during hepatic fibrosis. In the healthy liver, they metabolize and store retinoids. Upon activation by fibrogenic stimuli, quiescent HSCs transdifferentiate into myofibroblasts, lose their vitamin A, upregulate α-smooth muscle actin (αSMA), and produce collagen I. Various factors, including immune cell-derived fibrogenic molecules, growth factors, and lipopolysaccharide, as well as profibrotic lipid mediators such as lysophosphatidylinositol and lysophosphatidic acid, induce HSC activation in the course of chronic liver disease. TGF-β is the most HSC potent activator, which is produced by infiltrating lymphocytes and monocytes, Kupffer cells (KCs), and damaged hepatocytes. IL-17, produced by neutrophils and Th17 cells, sensitizes HSCs to TGF-β by upregulating TGF-β receptor II (TGF-βRII). In addition, platelet-derived growth factor (PDGF), which is produced by endothelial cells and macrophages, further promotes HSC activation. During fibrosis resolution, HSCs either die or revert to an inactive state by upregulating transcription factors such as peroxisome proliferator-activated receptor-γ (PPARγ), GATA-binding factor 4 (GATA4), GATA6, and transcription factor 21 (TCF21). NK and CD8+ T cells can eliminate activated HSCs by inducing apoptosis (Further abbreviations: GM-CSF, granulocyte/macrophage colony-stimulating factor; HH, hedgehog ligands; IHH, Indian Hedgehog; LPA, lysophosphatidic acid; LPI, lysophosphatidylinositol; LPS, lipopolysaccharide; miRNA, microRNA; MSR1, macrophage scavenger receptor 1; NF-κB, nuclear factor κ-light chain-enhancer of activated B cells; OPN, osteopontin; oxLDL, oxidized low-density lipoprotein; ROS, reactive oxygen species; S1P, sphingosine-1-phosphate; SHH, sonic hedgehog; TLR4, Toll-like receptor 4). Modified from reference [5].CC BY · PubMed Central
Figure 3 The path towards liver fibrosis: Kupffer cell activation and macrophage recruitment in the chronic inflammatory microenvironment of the diseased liver. (A) Ingestion of fat-laden apoptotic hepatocytes and free cholesterol activates KCs by promoting the production of proinflammatory mediators. (B) The liver’s chronic inflammatory microenvironment recruits monocytes from the circulation, which, due to local proinflammatory signaling, differentiate into monocyte-derived KC-like inflammatory, as well as lipid-associated, macrophages. (C) Macrophage populations are the major contributors in shaping both profibrotic and antifibrotic drivers within the fibrotic niche. Relevant phenotypic markers of the macrophage populations detected in mouse models are indicated in the figure (Abbreviations: CEACAM1, carcinoembryonic antigen-related cell adhesion molecule 1; CLEC4F, C-type lectin domain family 4 member F; LAM, lipid-associated macrophage; Mac1, macrophage-1 antigen; Mar1, macrophage scavenger receptor1; MMP, matrix metalloproteinase; SAM, scar-associated macrophages; SatM, segregated nucleus-containing atypical monocytes; TGF-β, transforming growth factor-β; TNF-α, tumor necrosis factor-α; VSIG4, V-set and immunoglobulin domain containing 4).
Figure 3 The path towards liver fibrosis: Kupffer cell activation and macrophage recruitment in the chronic inflammatory microenvironment of the diseased liver. (A) Ingestion of fat-laden apoptotic hepatocytes and free cholesterol activates KCs by promoting the production of proinflammatory mediators. (B) The liver’s chronic inflammatory microenvironment recruits monocytes from the circulation, which, due to local proinflammatory signaling, differentiate into monocyte-derived KC-like inflammatory, as well as lipid-associated, macrophages. (C) Macrophage populations are the major contributors in shaping both profibrotic and antifibrotic drivers within the fibrotic niche. Relevant phenotypic markers of the macrophage populations detected in mouse models are indicated in the figure (Abbreviations: CEACAM1, carcinoembryonic antigen-related cell adhesion molecule 1; CLEC4F, C-type lectin domain family 4 member F; LAM, lipid-associated macrophage; Mac1, macrophage-1 antigen; Mar1, macrophage scavenger receptor1; MMP, matrix metalloproteinase; SAM, scar-associated macrophages; SatM, segregated nucleus-containing atypical monocytes; TGF-β, transforming growth factor-β; TNF-α, tumor necrosis factor-α; VSIG4, V-set and immunoglobulin domain containing 4).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 224 references

Cited by

See all 197

Metadata

Authors
Akkız, H., Gieseler, R. K., & Canbay, A.
Affiliations
  • Bahçeşehir University (TR)
  • Universitätsklinikum Knappschaftskrankenhaus Bochum (DE)
Corresponding author
Akkız, Hikmet
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2024-07-18
Volume
25
Issue
14
Pages
7873
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4400775597
Cited by
191
References
223
Citations by year
2026: 112 · 2025: 70 · 2024: 9
FWCI
13.78
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • Preprints.org (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords
liver fibrosis, hepatic stellate cells, hepatic fibrogenesis, myofibroblast transdifferentiation, extracellular matrix deposition, hepatic stellate cell activation, HSC heterogeneity, macrophages, hepatocyte death, liver inflammation, antifibrotic therapy, cirrhosis reversal, cellular stress response, cytokines and chemokines
MeSH terms
Animals, Humans, Liver Cirrhosis, Hepatic Stellate Cells, Myofibroblasts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liver Fibrosis: From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells. https://app.cochat.ai/papers/10.3390/ijms25147873
The paper
Akkız, H., Gieseler, R. K., & Canbay, A. (2024). Liver Fibrosis: From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25147873

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.